Although TPS is successful at predicting response in NSCLC, emerging data in other solid tumors (gastric, bladder, breast, ovary) suggest the importance of immune cell PD-L1 expression to predict clinical outcomes with pembrolizumab (pembro). Data from KEYNOTE-012 (NCT01848834) and KEYNOTE-055 ...